Please select the option that best describes you:
Topics:
Medical Oncology • Internal Medicine • Myeloproliferative Neoplasms • Hematology • Benign Hematology
Is there a role for ruxolitinib in essential thrombocythemia?
In patients who are intolerant to hydroxyurea, anagrelide and interferon
Answer from: Medical Oncologist at Community Practice
There have been two larger publications supporting the use of ruxolitinib in ET. However, it is only useful in certain situations after standard therapies like hydroxyurea and pegylated interferon. Certainly, if a patient is symptomatic with cytokine-related symptoms, heading towards post-ET MF, or ...
Sign in or Register to read more